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INTRODUCTION
High-dose chemoradiotherapy with autologous bone
m a rrow or peripheral blood stem cell rescue is used incre a s-
ingly for the treatment of hematologic malignancies [1-9].
Although many of these illnesses occur with increasing fre-
quency in the older population, and despite the evidence
suggesting poorer prognosis of older patients with lymphoid
malignancies, high-dose therapy and autologous transplanta-
tion have traditionally been restricted to younger patients.
This practice is based on the premise that older patients may
not tolerate the intensity of this treatment, may be unable to
p rovide an adequate stem cell graft, or may have an overall
p o o rer prognosis [10-16]. Although increased morbidity with
i n c reasing age has been demonstrated for allogeneic marro w
transplantation, it is also known that older patients who
receive full-intensity standard therapies and tolerate them do
better than patients receiving compromised therapy [17,18].
Recently, several reports addressing the issue of age and
autologous transplantation indicate that in selected older
patients it is possible to obtain an adequate graft for trans-
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ABSTRACT
Although many hematologic malignancies are more common in older patients, autologous blood and marro w
transplantation (ABMT) has traditionally been restricted to patients younger than 60 years because of concerns
that older patients would be either unable to provide a graft or unable to tolerate the therapy. From June 1995 to
May 1998, 30 patients ≥60 years underwent ABMT at our institution for low-grade lymphoma (4 patients),
relapsed intermediate-grade lymphoma (17 patients), or multiple myeloma (9 patients). The median patient age
was 62.5 years (range 60-73). Pretransplantation conditioning regimens were CBV (cyclophosphamide, BCNU
[ c a rmustine], etoposide) or BEAM (carmustine, etoposide, cytarabine, melphalan) for intermediate-grade lym-
phoma patients and melphalan 140 mg/m2 + etoposide 60 mg/kg + total body irradiation 500 cGy for the others.
The rescue product was bone marrow (BM; 4 patients), peripheral blood stem cells (PBSC; 23 patients), or
BM+PBSC (3 patients). The median number of CD34+ cells/kg infused was 3.60 × 106 (range 0.53-31.0), by the
International Society for Hematotherapy and Graft Engineering method. The treatment-related mortality at day
100 and at 6 months was 10% and 16.7%, respectively. The median days to neutrophil >0.5 × 109/L was 11 (range
9-25) and platelets >20 × 109/L was 16 (range 6-70). Three patients died of infection (days 26, 27, and 38), and 1
died of an intracranial hemorrhage related to persistent thrombocytopenia (day 130). Bearman re g i m e n - re l a t e d
toxicity was moderate, with most toxicities ≤grade 2. Seven patients developed significant gut toxicity: 4 patients
with Clostridium difficile colitis and 3 patients with neutropenic enterocolitis. Depressive symptoms and signs were
noted in 4 patients. Three male patients developed decreased gonadal function after transplantation. These trans-
plantations accounted for 997 patient days, of which 266 days (27%) were in the outpatient BMT pro g r a m — a
smaller percentage than in patients <60 years (56%, P = .002). Twenty patients are alive 153 to ≥1224 days after
transplantation. ABMT in patients ≥60 years of age is feasible. Further studies addressing supportive care particu-
lar to older patients and comparisons of ABMT with traditional approaches to multiple myeloma and re l a p s e d
n o n - H o d g k i n ’s lymphoma in older patients are needed. Further work to identify elderly patients most likely to
benefit from this approach is also required.
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plantation and that these patients can tolerate and appear to
benefit from such therapy [19]. More understanding of the
feasibility and peculiarities of transplantation in older
patients is needed, because the combination of an incre a s-
ingly aged population and increasing patient consumerism
will result in greater numbers of these transplantations being
p e rf o rmed in coming years. We re p o rt on our early experi-
ence with autologous transplantation in patients >60 years
with low-grade non-Hodgkin’s lymphoma, interm e d i a t e -
grade non-Hodgkin’s lymphoma, and multiple myeloma and
o ffer observations re g a rding diff e rences in their course
compared with the course in younger patients.
MATERIALS AND METHODS
Patient Characteristics
Between June 1995 and May 1998, 30 patients ≥60 years
of age underwent high-dose therapy and autologous blood
and marrow transplantation (ABMT) for low-grade non-
H o d g k i n ’s lymphoma, intermediate-grade non-Hodgkin’s
lymphoma, or multiple myeloma. The median age at trans-
plantation was 62.5 years (range 60-73), and most patients
w e re men. Patients were eligible for transplantation if they
had an Eastern Cooperative Oncology Group (ECOG) per-
f o rmance score of 0 to 2, clinically adequate vital organ func-
tion defined as a multigated acquisition scan ejection fraction
g reater than 0.40, forced expiratory volume in 1 second and
d i ffusion capacity of carbon monoxide greater than 50% pre-
dicted for age and sex, creatinine <200 µmol/L, and liver
enzymes less than twice normal unless due to the underlying
m a l i g n a n c y. Other exclusion criteria included class 3 or 4
angina or myocardial infarction within 3 months pre c e d i n g
the transplantation, severe congestive heart failure (New Yo r k
H e a rt Association class 3 or 4), known dementia, hepatitis B
or C or HIV infection, and other active malignancies. Patient
demographics and disease characteristics are shown in Table 1 .
Patients 23 and 30 were transferred back to the re f e rr i n g
institution on day 1 as part of an interprovincial pro g r a m .
Data on their courses in hospital are not included because
they were not followed up at our center after day 1.
These 30 patients represent all patients over the age of
60 re f e rred for ABMT during the re p o rting period. All
30 patients proceeded to transplantation.
S a l v a ge Chemotherapy and Graft Collection
Most patients with non-Hodgkin’s lymphoma re c e i v e d
standard DHAP (dexamethasone, high-dose cytarabine, cis-
platin) or mini-BEAM (1,3-bis[2-chloro e t h y l ] - 1 - n i t ro s o u re a,
etoposide, cytarabine, and melphalan) salvage chemo-
therapy, or both. Two patients (1 and 5) received cyclophos-
phamide (4.5 g/m2) as salvage therapy because of pre v i o u s
h i s t o ry of renal insuff i c i e n c y. Peripheral blood stem cells
(PBSC) were preferentially collected after either the first or
the second cycle of salvage chemotherapy plus granulocyte
colony-stimulating factor (G-CSF; 5 µg/kg per day × 10 days).
Patients with multiple myeloma received 3 to 6 cycles of
vincristine, doxorubicin, and dexamethasone chemotherapy
b e f o re mobilization of PBSC with cyclophosphamide
(4.5 g / m2) and G-CSF (5 µg/kg per day × 10 days). Two × 10 L
leukophereses were performed using a Cobe Spectra (Cobe
Laboratories, Lakewood, CO) on days 9 and 10 of G-CSF
administration. Three patients (17, 20, and 27) had 3 phere-
ses because of poor CD34 counts and on the day after the
third pheresis underwent bone marrow harvest because of a
low CD34 count in the pheresis product. Four other
patients (5, 9, 19, and 29) underwent G-CSF–stimulated
bone marrow harvests (5 µg/kg per day × 5 days) pre-
f e rentially for logistical reasons. Specifically, because of
limited pheresis capabilities, we were unable to accommo-
date these 4 patients for pheresis in a medically acceptable
time frame.
High-Dose Chemoradiotherapy
Patients with intermediate-grade lymphoma re c e i v e d
either the CBV regimen (etoposide 2400 mg/m2 o v e r
6 hours on day –7, cyclophosphamide 1800 mg/m2 per day on
days –6 to –3, and BCNU 300 mg/m2 on day –2) or the
B E A M regimen (BCNU 300 mg/m2 on day –7, etoposide
2 0 0 mg/m2 per day on days –6 to –3, cytarabine 200 mg/m2
every 12 hours on days –6 to –3, and melphalan 140 mg/m2
on day –2) pretransplantation. Patients with low-grade
Table I . Demographics and Disease Characteristics*
Disease Status Prior to
Age at Salvage/Mobilization
Patient Transplant Sex Diagnosis Chemotherapy †
1 68 M IGL Partial Remission 1
2 66 M MM Partial Remission 1
3 61 M MM Refractory
4 60 M IGL Primary Refractory
5 73 M IGL Relapse 1
6 60 M IGL Relapse 1
7 68 F IGL Relapse 1
8 60 M LGL Relapse 1
9 65 M IGL Relapse 1
10 60 M IGL Relapse 1
11 61 M IGL Relapse 1
12 60 F LGL Partial Remission 1
13 61 F LGL Relapse 2
14 67 F MM Partial Remission 1
15 71 M IGL Relapse 1
16 62 M MM Refractory
17 62 F IGL Relapse 1
18 64 F MM Partial Remission 1
19 60 M IGL Primary Refractory
20 63 M IGL Relapse 2
21 60 F IGL Partial Remission 1
22 65 M MM Refractory 
23 60 M MM Partial Remission 1
24 65 F IGL Relapse 1
25 65 F IGL Relapse 1
26 64 F MM Partial Remission 1
27 69 M IGL Relapse 3
28 62 F IGL Relapse 1
29 60 F LGL Relapse 1
30 63 M MM Partial Remission 2
*M indicates male; F, female; IGL, intermediate-grade non-Hodgkin’s lym-
phoma; LGL, low-grade non-Hodgkin’s lymphoma; MM, multiple myeloma.
†Patients 2, 14, 23, 26, and 30 received an autologous transplantation as part
of a continued primary therapy plan. Their disease status was at the time of
h i g h -dose cyclophosphamide for stem cell mobilization. 
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l y mphoma and multiple myeloma received a combination of
etoposide 60 mg/kg over 6 hours on day –3, melphalan
140 mg/m2 over 30 minutes on day –2, and total body irra-
diation 500 cGy in a single fraction on day 0 [20]. All rescue
products were stored in the vapor phase of liquid nitrogen,
thawed in a 37°C water bath at the bedside, and injected by
means of an indwelling central venous catheter.
S u p p o rt i v e Care
Patients were nursed on a standard nursing unit and
p a rticipated in our outpatient transplant program [21]. All
patients received G-CSF (5 µg/kg per day subcutaneously),
s t a rting on day 1 until their absolute neutrophil count was
≥0.5 × 1 09/L. Platelets (random or single-donor) were
transfused to maintain a platelet count greater than 20 ×
1 09/L or if the patient was febrile (temperature greater than
38°C), greater than 30 × 1 09/L. Packed red blood cells
(PRBC) were given to maintain the hemoglobin at gre a t e r
than 90 g/L. All blood products were irradiated. Tw i c e
w e e k l y, oral trimethoprim-sulfamethoxazole was given as
p rophylaxis for Pneumocystis carinii pneumonia, start i n g
f rom the day of admission. Patients received acyclovir
(800 mg orally 3 times daily) for herpes simplex virus pro-
phylaxis. No other prophylactic antibiotics or antifungal
agents were used ro u t i n e l y. Febrile neutropenia (tempera-
t u re higher than 38°C and absolute neutrophil count of less
than 0.5 × 1 09/L) was treated with either a combination of
piperacillin and tobramycin or single-agent therapy with a
t h i rd-generation cephalosporin. Empiric vancomycin and
amphotericin B were added after 3 to 5 days and 5 to 7
days, re s p e c t i v e l y, for fever that persisted despite the use of
b ro a d - s p e c t rum antibiotics.
A n t i m i c robial therapy was further modified based on cul-
t u re results. Antimicrobial agents were continued until neu-
t rophil re c o v e ry (absolute neutrophil count greater than
0.5 × 1 09/L) and defervescence. Patients unable to maintain an
adequate oral caloric intake were fed whenever possible
t h rough a nasogastric tube or, if necessary, with total par-
enteral nutrition. Patients were discharged from the BMT ser-
vice to clinic once they were afebrile and ambulatory, had
achieved neutrophil re c o v e ry, had an adequate oral intake, had
transfusion re q u i rements that could be met through clinic
( requiring no more than 2 transfusions per week), and had no
other medical problems requiring them to remain in hospital.
RESULTS
Individual patient data on graft, transplantation, and
outcome are outlined in Table 2.
S a l v a ge Chemotherapy
Patient response to salvage chemotherapy followed by
transplantation is listed in Table 2. Patients were not for-
mally restaged after salvage therapy. Response to salvage was
based on some measure of clinically evaluable disease (eg,
peripheral nodes, M protein). Contaminated stem cells were
collected in patient 6 after 2 cycles of DHAP; therefore, he
subsequently received 2 cycles of mini-BEAM. Salvage with
mini-BEAM in this patient was also deferred by 3 months
because of exacerbation of preexisting angina. Further car-
diac investigation including coro n a ry angiography did not
identify any reversible coronary artery stenoses. The cardi-
ology consultants felt that with improved antianginal
m e dications, therapy could continue. Patient 9 responded to
initial salvage therapy; however, he pro g ressed before his
ABMT. Nevertheless, a decision was made to continue with
his transplantation. All other patients had stable re s p o n s e s
to salvage chemotherapy. The median number of CD34+
cells/kg collected was 3.60 × 1 06 (range 0.53-31.0) (Table 2).
Patients 9 and 20 were the only patients with less than our
usual CD34 threshold of 1.0 × 106 CD34+ cells/kg necessary
to undergo transplantation. Both patients, however, had
adequate nucleated cell counts (greater than 3.0 × 108/kg on
their harvested marrow or combined marrow and peripheral
blood) and for clinical reasons proceeded to transplantation.
Rescue Pr o d u c t
Twenty-three patients underwent a peripheral stem cell
transplantation: 4 had a bone marrow transplantation and 3
had a combined peripheral stem cell and bone marro w
transplantation. Our clinical practice at the time was to pref-
erentially use peripheral stem cells, when possible. However,
as indicated, 4 patients received bone marrow because of
scheduling reasons, and 3 other patients required bone mar-
row in addition to their peripheral stem cells because of
inadequate peripheral stem cell collections.
E n g r a f t m e n t
All patients followed up at our institution had neu-
t rophil re c o v e ry after  transplantation (Table 2). The
median time to re c o v e ry of neutrophils was 11 days (range
9-25). The median time to neutrophil re c o v e ry was not
delayed in these patients compared with patients younger
than 60 years of age transplanted during the same time
period at our institution (11 days; data not shown). Thre e
patients (14, 19, and 25) died before re c o v e ry of platelets.
For the remaining 25 patients at our institution, the median
time to platelets greater than 20 × 1 09/L was 16 d a y s
(range 6-70). Eleven patients, however, did not re c o v e r
their platelets for 20 or more days after transplantation and
w e re believed to have delayed re c o v e ry. The median num-
ber of days to platelet re c o v e ry was delayed in patients
older than 60 years compared with our younger patients
(13 days, P = .05; data not shown). The median number of
PRBC units transfused was 8 (range 2-26) and for platelets
16.5 (range 3-83). 
Tox i c i t y
Four patients died of transplantation-related complica-
tions. Three patients (14, 19, and 25) died from infection
while in hospital, and a fourth patient (17) died of complica-
tions of persistent thrombocytopenia. Patient 14 re q u i re d
p rolonged mechanical ventilation for re s p i r a t o ry failure sec-
o n d a ry to pneumonia. Multiorgan failure subsequently
evolved, and a decision to withdraw active treatment was
u n d e rtaken. Patient 19 had a very complicated course, which
included delayed neutrophil re c o v e ry and a hemicolectomy
for necrotic bowel secondary to neutropenic entero c o l i t i s .
While being mechanically ventilated in the intensive care
unit (ICU), the patient developed positive blood cultures for
Clostridium septicum. Despite aggressive antimicrobial ther-
a p y, he subsequently developed hemibody myonecrosis and
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re f r a c t o ry pneumonia. He died after withdrawal of active
c a re owing to the irreversibility of the myonecro s i s .
Patient 25 had a decreased level of consciousness sec-
o n d a ry to hyperosmolar hypern a t remia believed to be sec-
o n d a ry to diabetes insipidus. This was complicated by a
re spiratory arrest from aspiration pneumonia and acute res-
p i r a t o ry distress syndrome. While the patient was in ICU,
Staphylococcus hominis septicemia developed, and the patient
re q u i red continuous venovenous hemofiltration for acute
renal failure secondary to acute tubular necrosis. Multiorgan
failure persisted despite maximal supportive care, and a deci-
sion to withdraw treatment was made. Patient 17, who
e x p erienced persistent thrombocytopenia and platelet
re f r a c t o r iness after transplantation, died of an intracranial
hemorrhage 4.5 months posttransplantation.
The majority of patients had toxicities of grade 2 or less
a c c o rding to the Bearman re g i m e n - related toxicities scale
[22]. The most common moderate toxicities were stomatitis
and diarrhea. Seven patients (2, 5, 8, 16, 19, 22, and 28)
developed reversible cardiac dysfunction with congestive fail-
u re requiring therapy with diuretics with or without afterload
reducers. Two patients (14 and 15) developed grade 3 card i a c
toxicity and re q u i red ICU admission for atrial dysrh y t h m i a s
resistant to medical management on the ward. Patient 15 also
re q u i red mechanical ventilation for grade 3 pulmonary toxic-
ity owing to necrotizing bronchiolitis and alveolar damage
believed to be secondary to BCNU. This patient was tre a t e d
with high-dose cort i c o s t e roids, subsequently extubated suc-
c e s s f u l l y, and discharged from the hospital.
All patients developed neutropenic fevers and re q u i re d
broad-spectrum antibiotics. Patient 12 had esophageal can-
didiasis that responded to therapy with fluconazole. There
w e re no documented episodes of fungemia. Four patients
(3, 7, 22, and 27) developed significant C l o s t r i d i u m d i ff i c i l e
colitis that resolved with metronidazole therapy. Patient 22
developed enterococcus septicemia, which resulted in respi-
r a t o ry failure from aspiration pneumonia secondary to a
decreased level of consciousness. He required inotropic sup-
port, had a significant transaminitis that was believed to be
secondary to “shock liver” from hypotension, and had a pro-
longed stay in ICU because of several failed attempts at
extubation. Magnetic resonance imaging (MRI) revealed a
Table 2 .
Graft, Transplant, and Outcome Data*
Days to Days to Length of Stay Status and
CD34 + Cells in Type of Neutrophils Platelets in Days Response to Duration in Days
Patient Graft ( ×10 6/kg) Transplant >0.5 × 10 9/L >20 × 10 9/L (Outpatient Days) Transplant as of Oct. 31, 1998
1 4.25 PBSCT 10 16 21 (8) CR Relapse 454; Alive 764+
2 2.11 PBSCT 12 63 63 (35) VGPR Alive 411+
3 17.80 PBSCT 10 8 20 (2) VGPR Relapse 383; Dead 521
4 7.50 PBSCT 9 6 21 (14) CR Relapse 146; Dead 175
5 1.43 BMT 14 18 32 (11) CR Relapse 637; Alive 736+
6 2.96 PBSCT 10 16 19 (0) CR Dead 139
7 4.87 PBSCT 10 30 55 (0) CR Relapse 182; Dead 312
8 31.00 PBSCT 9 8 17 (7) CR Alive 1224+
9 0.53 BMT 11 9 20 (12) Prog Dis † Dead 149
10 10.3 PBSCT 9 12 28 (5) CR Alive 639+
11 15.45 PBSCT 19 35 36 (14) CR Alive 570+
12 12.81 PBSCT 10 20 16 (8) CR Alive 606+
13 13.20 PBSCT 11 15 25 (15) CR Alive 549+
14 1.15 PBSCT 11 X 42 (7) Toxic Death Dead 38
15 16.17 PBSCT 9 10 93 (7) CR Alive 589+
16 2.34 PBSCT 10 16 28 (4) VGPR Relapse 271; Dead 380
17 2.21 PBSCT + BMT 11 70 37 (9) CR Dead 130
18 1.96 PBSCT 12 20 28 (12) VGPR Alive 488+
19 2.53 BMT 21 X 33 (10) Toxic Death Dead 26
20 0.93 PBSCT + BMT 13 20 24 (8) CR Relapse 228; Alive 484+
21 17.96 PBSCT 10 10 22 (17) CR Alive 416+
22 2.9 PBSCT 16 50 99 (11) VGPR Alive 509+
23 ‡ 2.58 PBSCT Alive 409+
24 6.6 PBSCT 12 30 35 (11) CR Relapse 98; Alive 398+
25 6.36 PBSCT 10 X 34 (10) Toxic Death Dead 27
26 9.3 PBSCT 11 12 18 (11) VGPR Alive 348+
27 1.67 PBSCT + BMT 25 48 60 (8) CR Alive 230+
28 4.46 PBSCT 9 13 48 (7) CR Alive 187+
29 2.26 BMT 11 24 24 (3) CR Alive 162+
30 ‡ 2.23 PBSCT Alive 153+
*PBSCT indicates peripheral blood stem cell transplant; BMT, bone marrow transplant; X, did not recover; CR, complete remission; VGPR, very good partial
remission.
†Progressive disease (see text). 
‡Patients were transferred on day 1 to the referring institution.
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brain-stem infarct, and patient 22 required a tracheostomy
and percutaneous endoscopic jejunostomy tube because he
was believed to have a high risk of recurrent aspiration. He
recovered and was subsequently discharged to a rehabilita-
tion hospital. After an extended stay, patient 22 re c o v e re d
from his infarct and is living independently.
Two patients (2 and 28) developed neutropenic entero-
colitis, which resolved with medical management. Their
clinical picture was characterized by abdominal pain, ten-
derness, ileus, and bowel distention. Both patients required
ICU admission for 24 hours because of sepsis syndrome and
hypotension related to their enterocolitis despite bro a d -
s p e c t rum antibiotics. The symptoms of these patients
resolved rapidly after neutrophil re c o v e ry, and the patients
w e re eventually discharged from the hospital. Patient 6
experienced an upper gastrointestinal tract hemorrhage that
re q u i red increased platelet and red cell transfusions for
2 days but no other interventions.
Four patients (7, 14, 27, and 28) had severe and pro-
tracted anorexia and weight loss. They could not tolerate
nasogastric feedings at a rate sufficient for caloric re p l a c e-
ment and thus re q u i red total parenteral nutrition. Four
patients (2, 7, 13, and 24) experienced clinically signific a n t
d e p ression that re q u i red psychiatric consultation and phar-
macologic intervention. All 4 patients subsequently re c o v-
e red. Four patients (11, 14, 24, and 27) developed acute re n a l
f a i l u re secondary to nephrotoxic antimicrobial agents. They
did not re q u i re dialysis, and their renal function impro v e d
with hydration and discontinuation of the offending agents. 
Patient 29 had a generalized seizure believed to be due
to hypoxia from hypoventilation secondary to narc o t i c s .
This led to hypotension, which was felt to be responsible for
a subsequent right ventricular myocardial infarction and
c e re b rovascular accident complicating a high-grade caro t i d
artery stenosis. The patient was eventually transferred to the
referring hospital for ongoing rehabilitation.
Three of the 18 male patients (1, 5, and 10) presented
with symptoms of gynecomastia, diminished libido, and
erectile dysfunction. Hormonal levels confirmed the diagno-
sis of hyperg o n a d o t ropic hypogonadism. Two of these
patients responded to hormone supplementation with reso-
lution of symptoms and signs, whereas the third patient
declined replacement therapy.
Hospital Da y s
Our institution’s Outpatient Transplant Programme allows
patients who meet outpatient management eligibility criteria to
stay outside the hospital with assessments and therapies given
t h rough a 7-day-per-week, 12-hour- p e r- d a y, inpatient ward -
integrated outpatient unit [21]. As indicated, 3 patients died
while in the hospital after the 23rd, 24th, and 35th days. The
remaining 25 patients accounted for 997 patient days, of
which 266 patient days (approximately 27%) were delivere d
t h rough the outpatient program. This pro p o rtion of days in
the outpatient setting is less than for our patients under the
age of 60 (56%, P = .002; data not shown).
O u t c o m e
Of the 30 patients who received transplants, 20 are alive.
Ten lymphoma patients (8, 10, 11, 12, 13, 15, 21, 27, 28, and
29) are in clinical remission 5 to 40 months after transplan-
tation, whereas 4 patients (1, 5, 20, and 24) are alive with
relapsed intermediate-grade lymphoma. Of the 6 surv i v i n g
myeloma patients, 4 (2, 18, 22, and 26) remain in very good
p a rtial remission and are clinically well 11 to 17 months
posttransplantation. Patients 23 and 30 were transferred to
another center within days of receiving their high-dose
chemotherapy. They are alive and well 3 to 6 months post-
transplantation; however, their course in hospital and their
disease status are unknown.
Four patients (14, 17, 19, and 25) died of transplant-
related complications. Three patients (14, 19, and 25) died
in hospital. Six others (3, 4, 6, 7, 9, and 16) died after trans-
plantation, and 5 (3, 4, 7, 9, and 16) from relapsed disease.
Patients 3 and 16 developed pro g ressive myeloma after
transplantation and subsequently died 12 and 21 months
posttransplantation, respectively. Patient 4 suffered relapse 5
months after transplantation and died of progressive disease
1 month later. Patient 7, who had a protracted tre a t m e n t
course with C. difficile colitis and anorexia, suffered relapse 6
months posttransplantation and died 4 months later. Patient
9, who at transplantation had chemoresistant intermediate-
grade lymphoma after salvage chemotherapy, had pro g re s-
sive disease after  transplantation and died 5 m o n t h s
later. Patient 6, who had known coronary artery disease with
angina, died in complete remission 6 months after trans-
plantation following a massive myocardial infarc t i o n .
Autopsy confirmed his remission status.
DISCUSSION
High-dose therapy with autologous transplantation is
now standard therapy for patients with interm e d i a t e - g r a d e
lymphoma who have chemosensitive relapses and for
patients with multiple myeloma and is accepted therapy for
a number of other conditions [1-9]. The role of this
a p p roach in patients over age 60, however, remains to be
determined. The life expectancy of American and Canadian
people has risen over the years, and, by the year 2050, 20%
of the population is expected to be over the age of 65. This
means an estimated 100 million elderly people, most of
whom will be between the ages of 65 and 85, are expected to
be in relatively good health. Pre s e n t l y, the percentage of
seniors is estimated at 13% [23]. Predicted remaining years
of life for men and women in excellent health at age 65 is
18.1 and 21.5, respectively [24]. As the population ages in
better health, and hematologic malignancies remain more
common in this older group, physicians will need to esti-
mate the treatment benefits of intensive regimens in view of
their patients’ life expectancies. Welch et al. [25] have pro-
posed a framework that uses the declining exponential
a p p roximation for life expectancy to help clinicians gauge
the effect of competing risks as a function of age. They state
that, regardless of age, patients with more aggressive disease
have a greater potential survival gain from therapy. This is
important when considering that patients with advanced dif-
fuse non-Hodgkin’s lymphoma are rarely cured of their dis-
ease after conventional chemotherapy has failed, and that
multiple myeloma remains a fatal disease with a poor
median survival. Despite these factors, older patients with
relapsed or pro g ressive disease have traditionally been
excluded from high-dose regimens because of re p o rts of
Autologous Transplantation in Older Patients
209B B & M T
in c reased re g i m e n - related toxicities and poorer pro g n o s i s
c o m p a red with the younger population. However, data are
minimal comparing high-dose therapy and ABMT with con-
ventional dose treatment for these illnesses in the elderly. 
In recent years, significant advances have been made in
transplantation medicine, including the introduction of
peripheral stem cell transplantation with its shorter period
of absolute neutropenia and the use of hematopoietic
g rowth factors to hasten neutrophil engraftment after
a u t o logous transplantation or to mobilize peripheral blood
stem cells for use in transplantation. These advances have
given the impression of increased safety of autologous trans-
plantation [26-32]. For this reason, we have begun to per-
form autologous transplantation in patients over the age of
60 who meet general perf o rmance criteria. We re p o rt on
our early experience. Despite the heterogeneity of our
patients with respect to their underlying disease, cert a i n
observations can be made. 
All patients tolerated salvage therapy with DHAP,
mini-BEAM, or cyclophosphamide. Of the 26 patients who
p re f e rentially underwent scheduled peripheral stem
cell collections, 23 were able to have acceptable grafts col-
lected based on our existing threshold of a minimum of
1.0 3 1 06 C D 3 4+ cells/kg (>2.5 3 1 06 CD34 cells/kg pre-
f e rred). Three patients re q u i red autologous marrow to
augment an inadequate peripheral stem cell collection.
Four patients underwent bone marrow harvest in lieu of
peripheral stem cells for logistical reasons, and, of these,
1 patient had an inadequate harvest. With the small num-
bers in this series, it is difficult to make observ a t i o n s
re g a rding predictors of poor graft pro c u rement; however,
5 of the 9 myeloma patients had CD34 counts of less than
2.5 3 1 06 cells/kg. There is also a suggestion that heavily
p re t reated patients have an increased risk of being unable
to supply an adequate graft. Guba et al. [19] did not iden-
tify significant diff e rences in the number of cells collected
in 57 patients over 60 years of age. They did not addre s s ,
t h e re f o re, predictors of poor graft collection. These issues
need to be looked at prospectively in larger numbers of
transplant patients over the age of 60 years. The targ e t
CD34 dose also needs to be re c o n s i d e red in light of re c e n t
data suggesting that with ≥5 3 1 06 C D 3 4+ cells/kg, platelet
re c o v e ry time is shortened [33]. 
Although we have only the indirect data of pro p o rt i o n-
ately less time spent in the outpatient program and slower
platelet re c o v e ry compared with our younger patients dur-
ing the same time, there appears to be a greater degree of
toxicity and morbidity in patients older than 60 years. The
100-day mortality rate, however, in our 30 patients was
only 10%, similar to that in the re g i s t ry data for ABMT.
The 1-year nonrelapse mortality rate was 16.7%. Although
traditional re g i m e n - related toxicity measurements did not
appear to be significantly diff e rent qualitatively than in the
younger patients, other types of toxicities seemed to occur
in the older group. Specifically, as outlined, we observ e d
m o re serious episodes of gut toxicity, more cardiac and vas-
cular complications, more depression, and slower re c u p e r a-
tion after discharge. These observations are in keeping with
a previous re p o rt by Stamatoullas et al. [34], which sug-
gested a prolonged decline in perf o rmance status after
transplantation in older patients. Despite these toxicities,
our older patients were well enough to receive their tre a t-
ment in the outpatient setting about 25% of the time.
The patients in our study did not have significantly dif-
f e rent times to neutrophil re c o v e ry compared with the
younger group treated during the same time period. In con-
trast, median platelet re c o v e ry was delayed compared with
the younger patients at our center. It is unclear whether the
delayed platelet recovery seen in our patients represents an
a g e - related phenomenon or extensive pre t r a n s p l a n t a t i o n
therapy. As larger numbers of older patients are treated ear-
lier in the course of their disease, it will be important to
reassess this concern. If this is an age-related phenomenon
due to changes in marrow function, it would be necessary to
consider strategies to overcome it. The strategy could
include higher threshold numbers of CD34 cells for trans-
plantation or the use of megakaryocyte growth and develop-
ment factor, or other cytokines or growth factors as their
roles are defined.
The efficacy of these transplantations can be demon-
strated for those surviving disease-free or with very good
p a rtial remissions for the myeloma patients; however, the
place for high-dose therapy in transplantation for patients
over 60 years remains unclear. The question that needs to
be addressed is whether the morbidity and potentially
i n c reased short - t e rm mortality seen in these older patients
a re warranted by improved overall survival and quality-
adjusted life years compared with alternate salvage or with
the more common palliative approach taken with these
patients. Transplantation results may further improve in
this age group if the therapy is introduced earlier in the
course of the disease, as is presently the practice for
younger patients. Future studies, in collaboration with geri-
atricians, to identify prognostic indicators for the older
p a t i e n t ’s ability to tolerate therapy need to be pursued. For
example, there is a potential need for a more thorough pre-
transplantation cardiac and cere b rovascular assessment of
patients with known risk factors. Ultimately, the acceptance
of this approach to therapy in older patients will re q u i re
evidence from randomized control trials, demonstrating
superiority to current nontransplantation therapies.
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